GLP-1 Agonist Peptide Synthesis for High-Purity Scale-Up
Solution Overview
Problem
Existing processes for preparing glucagon-like peptide-1 (GLP-1) receptor agonists and their analogs, such as liraglutide, D-liraglutide, semaglutide, and D-semaglutide, are not scalable, economically viable, and do not achieve satisfactory purity profiles, making them unsuitable for industrial applications.
Innovation Solution
A chemical synthetic process using solid and solution phase methods employing FMOC strategy, involving anchoring dipeptide fragments to a resin, sequential coupling, and deprotection steps to form the desired peptide sequences, followed by purification to achieve high purity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If existing processes for preparing GLP-1 receptor agonists are used, then production can be achieved, but the purity profile is unsatisfactory and the processes are not scalable to industrial level
Solution Approach 1:
The patent segments the peptide synthesis into modular solid-phase synthesis steps with orthogonal protection strategies (Fmoc for N-terminal, Boc for side chains). This segmentation allows each coupling cycle to be optimized independently for high purity while maintaining scalability through standardized reusable protocols across multiple batches.
2Manufacturing precision
If existing synthetic schemes are used, then GLP-1 receptor agonists can be prepared, but the processes are complex and not economically viable for industrial application
Solution Approach 1:
The patent employs preliminary orthogonal protection of amino acid side chains (Boc protection of Lys, Arg, His residues) before peptide assembly. This preliminary action prevents unwanted side reactions during synthesis, ensuring high purity without requiring complex purification steps, thereby simplifying the overall process while maintaining precision.
3Manufacturing precision
If existing processes are used, then GLP-1 receptor agonists can be produced, but they are not economically viable and difficult to implement at industrial level
Solution Approach 1:
The solid-phase synthesis methodology is self-service in nature, where the resin-bound peptide automatically directs the sequence of reactions through orthogonal deprotection and coupling cycles. This self-directing mechanism eliminates the need for complex external control systems and manual intervention at each step, making the process inherently easier to implement and scale industrially while maintaining high purity.
Data Source
AI summary
The present invention relates to the processes for preparing glucagon-like peptide-1 (glp-1) receptor agonists and their analogs. The present invention further relates to processes for preparing liraglutide, D-liraglutide, semaglutide and D-semaglutide. The present invention specifically relates to processes for preparing glucagon-like peptide-1 (glp-1) agonist and their analogs, wherein the liraglutide, D-liraglutide, semaglutide and D-semaglutide produced are substantially pure. The present invention also relates to preparation of glucagon-like peptide-1 (glp-1) agonist and their analogs by solid and solution phase method.